Skip to main content
Cancer Explained
Donate

NewsTrending topic

The EU adopts Europe's Beating Cancer Plan

The EU adopts Europe's Beating Cancer Plan (European Union, 2021). What changed, who is affected, and what it does and doesn't mean.

By Cancer Explained Editorial TeamPublished Updated

Original commentary from the Cancer Explained editorial team.

Five adults in activewear walk and chat together along a sunlit park path, one wearing a head scarf.
Walking Group — illustrative photograph, not of anyone named in this story.

Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.

A plan with numbers attached

On 3 February 2021 the European Commission adopted Europe's Beating Cancer Plan. It is a policy framework, not a law. Each country still runs its own health service. What the plan does is set shared goals, pay for part of the work, and put dates on the goals.

The Commission's own document gives the scale. In 2020, 2.7 million people in the EU were told they had cancer. Another 1.3 million died of it. Europe has about a tenth of the world's people and about a quarter of its cancer cases. The plan sets aside 4 billion euros across EU funding tools. Of that, 1.25 billion euros comes from the EU4Health program.

Ten flagship initiatives sit under four areas: prevention, early detection, treatment, and quality of life. Three of the targets are worth knowing, because each rests on a test or a vaccine you can ask about yourself.

Target one: fewer than 5% using tobacco

The plan aims for a "tobacco-free generation" by 2040, meaning fewer than 5% of people in the EU use tobacco. About 25% did when the plan was written.

Tobacco is the clearest single lever. Smoking is tied most strongly to lung cancer, and lung cancer kills more Americans than any other cancer. For 2026 the American Cancer Society projects 229,410 new US cases and 124,990 deaths, the figures SEER, the US surveillance program, carries.

Stage matters here more than almost anywhere. SEER data for 2016 to 2022 show 5-year relative survival of 65.5% when lung cancer is still localized, meaning it has stayed in the lung. It is 10.5% once the cancer is distant, meaning it has reached other organs. Only 24% of US lung cancers are caught while still localized. Those are group figures. They do not forecast any one person's course. Our guide to quitting smoking covers what actually helps.

Target two: 90% of girls vaccinated against HPV

The plan aims to vaccinate at least 90% of the EU's target group of girls by 2030, and to raise vaccination among boys sharply.

Human papillomavirus (HPV) is a common virus passed by skin-to-skin sexual contact. Most infections clear on their own. Infection that lasts with certain HPV types causes nearly all cervical cancer, plus a share of anal, vulvar, vaginal, penile and throat cancers. The vaccine works before exposure, which is why it is given in early adolescence rather than later. NCI describes the same logic for the US program. You can read more in our plain guide to the HPV vaccine.

Target three: screening offered to 90%

The fourth flagship is a new EU screening scheme, meant to ensure 90% of eligible people are offered breast, cervical and colorectal screening by 2025. The plan is blunt about why. Coverage then ranged from 6% to 90% between countries for breast screening, and from about 25% to 80% for cervical screening.

What do those three tests do? The US survival percentages below all come from people diagnosed between 2016 and 2022.

  • Breast. A mammogram is a low-dose x-ray of the breast. It can show a lump too small to feel. SEER puts 5-year relative survival at 100.0% for localized female breast cancer and 33.8% once it is distant.
  • Cervical. A Pap test looks at cervical cells; an HPV test looks for the virus. Both can catch changes before cancer starts, so treatment can prevent the cancer rather than treat it. Localized cervical cancer carries 91.8% 5-year relative survival, against 20.5% for distant disease.
  • Colorectal. A colonoscopy or a stool test looks for polyps, which are growths that can turn cancerous over years. Removing a polyp removes the future cancer. Localized colorectal cancer carries 91.3% 5-year survival, against 16.9% when distant.

In each case, the test is doing the same job: moving diagnosis to the left, into a stage where surgery alone often works. Our overview of cancer screening explains how programs are built, and benefits and harms of screening covers the real trade-offs.

When to get checked

Screening ages differ by country. These signs, though, are worth a same-week call to a clinician anywhere:

  • Bleeding between periods, after sex, or after menopause
  • A new breast lump, skin dimpling, or nipple discharge with blood
  • Blood in the stool, or a change in bowel habits lasting more than three weeks
  • A cough that lasts more than three weeks, or coughing up blood
  • Unplanned weight loss of more than 5% of body weight in six months

What this does not mean

  • The plan cannot order any country to deliver screening or vaccination. The targets are commitments the Commission funds and tracks, not binding rules.
  • Meeting a 90% "offered screening" target is not the same as 90% of people attending. Uptake is a separate number.
  • A target set in 2021 is not a report of what happened. Check current national guidance for where you live.
  • The survival percentages here describe large groups over past years. They are not a prediction for any individual.

Sources

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.

Know someone who needs this?

Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.

Email itText itWhatsApp

Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.

Put the story in context

Prevention, possible warning signs, screening, and diagnosis

This story relates to Cancer. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.

  • Prevention and risk reduction

    Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.

    NCI prevention information

  • Symptoms and possible early signs

    Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.

    NCI signs and symptoms

  • Screening and early detection

    Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.

    NCI cancer screening information

  • How cancer is diagnosed

    Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.

    NCI diagnosis information

A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.

Go deeper with NCI